|
|
|
|
arGentis Receives Favorable Opinion For European Orphan Drug Designation
arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the company's product candidate ARG201 (native type 1 bovine...
|
|
|
arGentis Receives Favorable Opinion for European Orphan Drug Designation
arGentis anticipates the confirmation process by the European Commission should be finalized in early 2009.Once confirmed, arGentis' subsidiary, arGentis Autoimmune Europe, LTD will gain access to incentives including 10 years...
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Recepto
These novel antagonist candidates have been created through our ongoing structure-activity relationship studies of oligonucleotides, through which we have also identified agonists of TLR7, 8 and 9, said Sudhir Agrawal, D.Phil., Chief...
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Recepto
Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have...
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for
Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have...
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Recepto
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9....
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Recepto
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA - News) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7...
|
|
|
Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Recepto
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9....
|
|
|
Steroid Trial Helps in Differential Diagnosis of Autoimmune Pancreatitis
_ Steroid Trial Helps in Differential Diagnosis of Autoimmune Pancreatitis.
|
|
|
Involvement of the Apoptotic Mechanism in Pemphigus Foliaceus Autoimmune Injury of the Skin
Li N et al.- Findings show that biochemical events of apoptosis are provoked in the epidermis injected with PF autoantibodies. Caspase activation may contribute to acantholytic blister formation in PF. Involvement of the Apoptotic...
|
|
|
The Incidence of Autoimmune Thyroid Disease: A Systematic Review of the Literature
_ The Incidence of Autoimmune Thyroid Disease: A Systematic Review of the Literature.
|
|
|
Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lup
Risk variant of STAT4 (T allele; rs7574865) was simultaneously associated with lower serum IFN- activity and greater IFN--induced gene expression Risk allele of STAT4 was associated with increased sensitivity to IFN- signaling IFN regulatory...
|
|
|
VLST Corporation And Novo Nordisk Announce Collaboration Agreement To Develop Therapeutics For Autoimmune And
Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, announced that the companies have entered into an exclusive, worldwide...
|
|
|
Archemix Secures Partnership with Glaxo to Develop Drugs for Inflammatory Diseases
Biotech, Autoimmune, deals Luke Timmerman 12/23/08 (Update: The first paragraph includes information that seven drugs are subject to the partnership, and the final paragraph includes comment from Archemix about this deals impact on its...
|
|
|
Autoimmune Pancreatitis: Disease Evolution, Staging, Response Assessment, and CT Features That Predict Respons
Sahani DV et al.- CT features like diffuse swelling and halo respond favorably to CST and likely reflect an early inflammatory phase, whereas features like ductal strictures and focal masslike swelling are predictive of a suboptimal...
|
|
|
HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation
Zignego AL et al.- Hepatitis B (HBV) and C (HCV) viruses differ both in viral structure and in natural history of chronic infection. HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation.
|
|
|
Research and Markets: New Autoimmune Disease Series Report: Will Biologics Emerge as New Treatments for Reacti
Reactive arthritis (ReA), a seronegative spondyloarthropathy that is believed to be partially autoimmune and triggered by the presence of a bacterial infection, is rare.For that reason, along with the availability of generic agents and...
|
|
|
Scientists Discover Trigger for Autoimmune Diseases
MONDAY, Dec.22 (HealthDay News) -- Healthy adults have potential autoimmune disease-causing cells, but these cells stay in an 'off' state, a U.S. study shows. Immune cells that attack the body cause autoimmune diseases such as...
National Womens Health Information Center:
Dec 22 2008 4:24PM
Matching: autoimmune immune
|
Find similar documents
|
|
|
|
Scientists Discover Trigger for Autoimmune Diseases
MONDAY, Dec.22 (HealthDay News) -- Healthy adults have potential autoimmune disease-causing cells, but these cells stay in an 'off' state, a U.S. study shows. Immune cells that attack the body cause autoimmune diseases such as...
|
|
|
Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer
Kamisawa T et al.- In elderly male patients presenting with obstructive jaundice and a pancreatic mass, AIP should be considered in the differential diagnosis. Based on a combination of clinical, serological, and radiological findings,...
|
|
|
Prevention of Corneal Abrasions in Patients with Autoimmune Dry Eyes
_ Prevention of Corneal Abrasions in Patients with Autoimmune Dry Eyes.
|
|
|
GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance
Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases LONDON & PHILADELPHIA & BERKELEY, Calif.-- (BUSINESS WIRE) -- GlaxoSmithKline (LSE:GSK) (NYSE:GSK) and Dynavax Technologies...
|
|
|
OTCPicks.com: OTCPicks.com Stocks to Watch for Thursday, December 18th DVAX, ANSV, CNST, CNLG, ACTC
Our Stocks to Watch tomorrow include Dynavax Technologies Corp.(Nasdaq: DVAX), Anesiva Inc. (Nasdaq: ANSV), Constar International Inc. (Nasdaq: CNST), Conolog Corp. (Nasdaq: CNLG) and Advanced Cell Technology Inc. (OTC: ACTC).
|
|
|
OTCPicks.com: OTCPicks.com Stocks to Watch for Thursday, December 18th DVAX, ANSV, CNST, CNLG, ACTC
(M2 PRESSWIRE via COMTEX) -- DVAX | Quote | Chart | News | PowerRating -- Our Stocks to Watch tomorrow include Dynavax Technologies Corp.(Nasdaq: DVAX), Anesiva Inc. (Nasdaq: ANSV), Constar International Inc. (Nasdaq: CNST), Conolog...
|
|
|
VLST Snags Partnership with Novo Nordisk to Develop New Drugs for Autoimmunity
Biotech, deals, Autoimmune Luke Timmerman 12/17/08 VLST has nailed down its first partnership with a major pharmaceutical company.The Seattle biotech is announcing today it has formed an exclusive, worldwide collaboration that will...
|
